ArticleMicrobial drug resistance (Larchmont, N.Y.)2018
Molecular Characterization of Carbapenem-Resistant Acinetobacter baumannii in the Intensive Care Unit of Uruguay's University Hospital Identifies the First rmtC Gene in the Species.
Article in Microbial drug resistance (Larchmont, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- Changing landscape of 16 S-RMTase-mediated aminoglycoside resistance in clinical Klebsiella pneumoniae isolates from Chile between 1997 and 2023.Scientific reports · 2026Article
- Phylogenomic analysis of aquatic and clinical OXA-23-positiveOne health (Amsterdam, Netherlands) · 2025Article
- Persistent multispecies dissemination ofJournal of clinical microbiology · 2025Article
- Phenylacetic acid catabolism modulates virulence factors and drug resistance in Acinetobacter baumannii MCC 2076.World journal of microbiology & biotechnology · 2025Article
- Molecular epidemiology of carbapenem-resistantmSphere · 2025Article
- First Detection of High-Level Aminoglycoside-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Burden of severe infections due to carbapenem-resistant pathogens in intensive care unit.World journal of clinical cases · 2023Review
- Global scenario of the RmtE pan-aminoglycoside-resistance mechanism: emergence of theMicrobial genomics · 2023Article
- Novel Resistance Regions Carrying TnAntibiotics (Basel, Switzerland) · 2023Article
- Research Updates of Plasmid-Mediated Aminoglycoside Resistance 16S rRNA Methyltransferase.Antibiotics (Basel, Switzerland) · 2022Review
- Imported One-Day-Old Chicks as Trojan Horses for Multidrug-Resistant Priority Pathogens HarboringApplied and environmental microbiology · 2022Article
- Synergism of imipenem with fosfomycin associated with the active cell wall recycling and heteroresistance in Acinetobacter calcoaceticus-baumannii complex.Scientific reports · 2022Article
- Carbapenem-resistantFrontiers in microbiology · 2022Review
- Population genomics and antimicrobial resistance dynamics of Escherichia coli in wastewater and river environments.Communications biology · 2021Article
- Aminoglycoside Resistance: Updates with a Focus on Acquired 16S Ribosomal RNA Methyltransferases.Infectious disease clinics of North America · 2020Review
- Clonal Dissemination of Clinical Isolates of Acinetobacter baumannii Carriers of 16S rRNA Methylase Genes in an Oncological Hospital in Recife, Brazil.Current microbiology · 2020Article
- Comparative Genomics ofFrontiers in microbiology · 2020Article
- Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings.Revista da Sociedade Brasileira de Medicina Tropical · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are an increasing concern in intensive care units (ICUs) worldwide. The combination of carbapenemases and 16S rRNA-methyltransferases (16S-RMTases) further reduces the therapeutic options. OXA-carbapenemase/A. baumannii clone tandems in Latin America have already been described; however, no information exists in this region regarding the occurrence of 16S-RMTases in this microorganism. In addition, the epidemiology of A. baumannii in ICUs and its associated resistance profiles are poorly understood. Our objectives were as follows: to study the clonal relationship and antibiotic resistance profiles of clinical and digestive colonizing A. baumannii isolates in an ICU, to characterize the circulating carbapenemases, and to detect 16S-RMTases. Patients admitted between August 2010 and July 2011 with a clinically predicted hospital stay > 48 hr were included. Pharyngeal and rectal swabs were obtained during the first fortnight after hospitalization. Resistance profiles were determined with MicroScan
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.